3807-56-5

Usage

Uses

Used in Pharmaceutical Industry:
2,5-DIMETHYL-1-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its unique structure allows it to be a versatile component in the creation of potential therapeutic agents, contributing to the advancement of medicinal chemistry.
Used in Chemical Research:
In the field of chemical research, 2,5-DIMETHYL-1-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID is employed as a key building block for the synthesis of complex organic molecules. Its reactivity and structural features make it an essential component in the exploration of new chemical reactions and the discovery of novel materials with potential applications in various industries.
Used in Medicinal Chemistry:
2,5-DIMETHYL-1-PHENYL-1H-PYRROLE-3-CARBOXYLIC ACID is utilized as a structural component in the design and synthesis of new drugs. Its presence in molecular frameworks can influence the pharmacological properties of the resulting compounds, making it a crucial element in the development of innovative therapeutic agents.

InChI:InChI=1/C13H13NO2/c1-9-8-12(13(15)16)10(2)14(9)11-6-4-3-5-7-11/h3-8H,1-2H3,(H,15,16)

Upstream product

• 76546-68-4 2,5-dimethyl-1-phenyl-1H-pyrrole-3-carboxylic acid ethyl ester 
• 83-24-9 2,5-dimethyl-1-phenyl-1H-pyrrole 
• 124-38-9 carbon dioxide 
• 129435-59-2 3-<1-hydroxy-(2-methylthio)propyl>-4-methyl-1-phenylazetidin-2-one 
• 129435-60-5 (E)-3-(2-hydroxypropylidene)-4-methyl-1-phenylazetidin-2-one 
• 2833-28-5 trans-4-oxo-2-pentenoic acid 
• 81942-10-1 4-methyl-1-phenylazetidine-2-one 
• 129435-69-4 (E)-4-hydroxy-2-(1-phenylaminoethyl)pent-2-enoic acid 
• 129435-80-9 methyl 2,5-dimethyl-1-phenyl-1H-pyrrole-3-carboxylate 
• 62-53-3 aniline 
• 129435-58-1 4-methyl-3-(2-methylthio)propionyl-1-phenylazetidin-2-one 
• 85392-47-8 methyl 2-acetyl-4-oxovalerate 

Relevant academic research and scientific papers

Beta-LACTAMASE INHIBITOR

The present invention addresses the problem of providing a compound having a beta-lactamase inhibitory activity. The problem is solved by a compound which is represented by general formula (1) that represents a compound in which a specific location of a 5

Screening of a Custom-Designed Acid Fragment Library Identifies 1-Phenylpyrroles and 1-Phenylpyrrolidines as Inhibitors of Notum Carboxylesterase Activity

The Wnt family of proteins are secreted signaling proteins that play key roles in regulating cellular functions. Recently, carboxylesterase Notum was shown to act as a negative regulator of Wnt signaling by mediating the removal of an essential palmitoleate. Here we disclose two new chemical scaffolds that inhibit Notum enzymatic activity. Our approach was to create a fragment library of 250 acids for screening against Notum in a biochemical assay followed by structure determination by X-ray crystallography. Twenty fragments were identified as hits for Notum inhibition, and 14 of these fragments were shown to bind in the palmitoleate pocket of Notum. Optimization of 1-phenylpyrrole 20, guided by structure-based drug design, identified 20z as the most potent compound from this series. Similarly, the optimization of 1-phenylpyrrolidine 8 gave acid 26. This work demonstrates that inhibition of Notum activity can be achieved by small, drug-like molecules possessing favorable in vitro ADME profiles.

Discovery of novel Tetrahydrobenzo[b]thiophene and pyrrole based scaffolds as potent and selective CB2 receptor ligands: The structural elements controlling binding affinity, selectivity and functionality

CB2-based therapeutics show strong potential in the treatment of diverse diseases such as inflammation, multiple sclerosis, pain, immune-related disorders, osteoporosis and cancer, without eliciting the typical neurobehavioral side effects of CB1 ligands. For this reason, research activities are currently directed towards the development of CB2 selective ligands. Herein, the synthesis of novel heterocyclic-based CB2 selective compounds is reported. A set of 2,5-dialkyl-1-phenyl-1H-pyrrole-3-carboxamides, 5-subtituted-2-(acylamino)/(2-sulphonylamino)-thiophene-3-carboxylates and 2-(acylamino)/(2-sulphonylamino)-tetrahydrobenzo[b]thiophene-3-carboxylates were synthesized. Biological results revealed compounds with remarkably high CB2 binding affinity and CB2/CB1 subtype selectivity. Compound 19a and 19b from the pyrrole series exhibited the highest CB2 receptor affinity (Ki= 7.59 and 6.15 nM, respectively), as well as the highest CB2/CB1 subtype selectivity (～70 and ～200-fold, respectively). In addition, compound 6b from the tetrahydrobenzo[b]thiophene series presented the most potent and selective CB2 ligand in this series (Ki= 2.15 nM and CB2 subtype selectivity of almost 500-fold over CB1). Compound 6b showed a full agonism, while compounds 19a and 19b acted as inverse agonists when tested in an adenylate cyclase assay. The present findings thus pave the way to the design and optimization of heterocyclic-based scaffolds with lipophilic carboxamide and/or retroamide substituent that can be exploited as potential CB2 receptor activity modulators.

Quinoline derivatives and their use

The invention discloses a quinoline derivative and a usage thereof, a compound with a structure as shown in a formula (I) and or a pharmaceutically acceptable salt of the compound. The compound or the pharmaceutically acceptable salt thereof disclosed by the invention can be applied to the field of preparation of drugs for preventing or treating tumors.